Analysis of the indications layout of PD-1/L1 mono-resistant.

Introduction: A text understands the differencebetween between China and the United States that have been approved for indicationsLung cancer is a preferred indication of both Chinese and American biopharmaceutical companies, with the number of approvals ranking first!---- Second, in the United States, the top six cancer species, China has the hunting involvedAccording to the type of cancer, the number of domestic enterprises in the study of indications is significantly higher than the number of multinational enterprises, lymphoma and nasopharyngeal cancer multinational enterprises are not involvedIn China, the development stage of indications by combination drug and single drug classification analysis, the results show that the number of joint drug development is higher than single drug treatment, lung cancer, liver cancer, stomach cancer, breast cancer and other common indications are the most prominentThe first PD-1 inhibitor was approved in 2014, and immunotherapy has broken through the bottleneck in tumor treatment and brought about new treatment changesIn the previous report, we analyzed the joint drug use study of PD-1/PD-L1, and compared the differences between multinational pharmaceutical companies and local enterprises in joint drug use clinical trialsAnd in recent years, with more similar products listed, a variety of indications have been approved, in the face of PD-1/PD-L1 single-resistance market such a large piece of cake, various types of enterprises how to adapt to the strategic layout, to carry out differentiated competitionThis report explores the similarities and differences between indications and each other in various dimensions, from the three dimensions of china and the United States, multinational and domestic enterprises, combined drugs and single medicineThe difference between China and the United States with approved indications first summarizes The PD-1/PD-L1 inhibitors approved for indications in the United States and China, and the United States is far ahead of China in overall numbersSince 2014, when Paboli Zuma in Mershadon was approved by the FDA, PD-1/PD-L1 inhibitors approved in the United States have basically covered common diseases such as lung cancer, urethra skin cancer, melanoma, and 19 cancers and 26 adaptationsChina's first domestic PD-1 inhibitor is approved in December 2018, The Real Creatures of The Riveri monotonica, and the current domestic enterprises approved the largest degree of adaptation of The Karelli Beads monoidatal (Hengrui) is only 4Mainly because China's immunotherapy research and development started late, research and development strength is relatively backwardFrom the perspective of the type of indications between China and the United States, lung cancer is a preferred indications between China and the United States, the number of approvals are ranked firstSecond, in the united States, the top six cancer species, China has involved in hunting, are non-small cell lung cancer (non-small cell lung cancer and small cell lung cancer), liver cancer, melanoma, head and neck scale cancer and lymphoma, showing homogenizationIt is worth suggesting that lymphoma, stomach cancer and esophageal cancer, the number of approved indications in China is similar to, or even exceeded, in the United StatesCombined with epidemiological statistics, we can get a glimpse of the differences between China and the United States in the choice of indications According to the latest cancer statistics released by China and the United States, lung cancer ranks first in the incidence of lung cancer in China and second among Men in the United States, explaining from the side the research and development momentum and market space generated by the large patient base In the United States urinary skin cancer, melanoma, kidney cancer is a common tumor, China's digestive system tumor incidence and mortality rate is higher, such as stomach cancer, esophageal cancer and so on As to why melanoma and Hodgkin's lymphoma are highly approved in China? Research and development developers speculated that this is because in cancer options, domestic companies will learn from the successful experience of multinational enterprises, Paboli zuma and Navuliu monotoma in the United States approved the first indications are melanoma, and in 2017 and 2016, respectively, approved Hodgkin's lymphoma indications, providing a mature clinical experience The differences between the layout of multinational enterprises and domestic enterprises in China Multinational enterprises and domestic enterprises in China approved a total of 18 PD-1/PD-L1 inhibitors, respectively, in the following figure A total of 10 indications were achieved by multinational enterprises, 6 of which were lung cancer species, and domestic enterprises approved a total of 8 indications, three of which were third-line treatment of Hodgkin's lymphoma Among them, Navuliyu monotophoid gastric cancer indications are more special, in March 2020 in China approved, this time earlier than the United States, which shows the precise layout of multinational enterprises around the world Let's see how the layout of multinational enterprises and domestic enterprise stoicism is different in the development phase? The statistical development stage (including pre-clinical, clinical application, clinical, listing application stage), the total number of the top 15 indications, lung cancer, liver cancer, stomach cancer, lymphoma, breast cancer ranked in the top five Whether multinational or domestic enterprises, the largest number of overall indications development is still lung cancer According to the type of cancer, the number of domestic enterprises in the study of indications is significantly higher than the number of multinational enterprises, lymphoma and nasopharyngeal cancer multinational enterprises are not involved Compared with approved indications, the number of developments of gastric cancer, liver cancer and esophageal cancer increased significantly, and the overall research and development layout was similar to that of cancer incidence in China According to the 2015 Analysis of Malignant TumorS in China, the top six incidence sofa incidences in China in 2015 were lung cancer, stomach cancer, colorectal cancer, liver cancer, breast cancer and esophageal cancer, and lymphoma ranked 10th in cancer mortality What are the differences in the layout of individual drugs in indications? Statistics of the number of Chinese market indications of the top ten drugs, the overall research and development strength of multinational enterprises has been approved in the country four drugs (Paboli zhu monotophono, atalijuzumab, Navuliu monotonicaandatis and degree svaloliu monotophonosis), the number of indications coverage is also the most extensive Among domestic enterprises, Hengrui's Karelli Pearl Singanti-Resistance research and development strength can not be underestimated, the layout of indications 42, the number of more than multinational enterprises; Applications for listing of small cell lung cancer, non-scaly non-small cell lung cancer and hepatocellular cancer were filed, and The Rhaplincarite also submitted applications for listing of nasopharyngeal cancer and urinary tract skin cancer in May 2020 Although the TQB2450 and the HLX10 of Fuhong Hanxuan have not been approved, the coverage of indications is relatively extensive What are the differences in the layout of individual drugs in various types of indications? Eight PD-1/PD-L1 inhibitors listed in China have a first-mover advantage, each single antiphobic in the field of lung cancer has a research project layout; Cancer; Tripri sing-it-againstness is more of an indication that melanoma, liver, nasopharyngeal and breast cancer serosinous; reelizumab is liver cancer, esophageal cancer, urinary skin cancer and stomach cancer; and Cindilli supavirus is lymphoma and esophageal cancer Carilli BeadSaand and Trepri Singer are diverse and have a wider coverage In terms of multinational companies, the four drugs listed are more extensive, with Paboli beads being the most resistant Compared with domestic enterprises, there are more projects in prostate cancer, head and neck scale cancer, pee path cancer, kidney cancer and other indications, and fewer research projects on indications such as nasopharyngeal cancer, stomach cancer and lymphoma The difference between combination drug and monodrug indications in order to overcome the problem of low objective mitigation rate and efficacy bottleneck of immunosingle drug therapy, combined drug use has gradually become a new treatment choice, and a large number of clinical studies are under way The analysis of indications in China at the development stage by combination drug and single drug classification shows that the number of development of combination drug is higher than that of single drug treatment, with lung cancer, liver cancer, stomach cancer, breast cancer and other common indications being the most prominent However, in some indications, the number of development of single drug therapy is higher than that of combination drugs, which is reflected in the indications of melanoma, lymphoma, nasopharyngeal cancer, cervical cancer, endometrial cancer, and so on, with the largest number of lymphomas Related: Sieger Rebecca L, Miller Kimberly D, Goding Sauer Ann, et al Colorectal Cancer Statistics, 2020 (J CA: a cancer journal clinician fors, 2020, 70 (3) Sun Kexin, Zheng Rongshou, Zhang Thinking, et al 2015 Analysis of the Incidence and Death of Malignant Tumors in China Sub-regions Chinese Tumors, 2019, 28 (01): 1-11.